Atormac
brintellex
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 913  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (97 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References

 Article Access Statistics
    Viewed3260    
    Printed60    
    Emailed1    
    PDF Downloaded225    
    Comments [Add]    

Recommend this journal

 


 
LETTER TO EDITOR
Year : 2007  |  Volume : 55  |  Issue : 4  |  Page : 416

Survival in rhinocerebral mucormycosis: Is iron the key?


Department of Medicine, Christian Medical College and Hospital, Vellore - 632 004, Tamil Nadu, India

Date of Acceptance13-Oct-2007

Correspondence Address:
Pavan Bhargava
Department of Medicine, Christian Medical College and Hospital, Vellore - 632 004, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.37101

Rights and Permissions



How to cite this article:
Bhargava P. Survival in rhinocerebral mucormycosis: Is iron the key?. Neurol India 2007;55:416

How to cite this URL:
Bhargava P. Survival in rhinocerebral mucormycosis: Is iron the key?. Neurol India [serial online] 2007 [cited 2020 Jul 9];55:416. Available from: http://www.neurologyindia.com/text.asp?2007/55/4/416/37101


Sir,

I read with great interest, the study by Jayalakshmi et al. , regarding factors for survival in rhinocerebral mucormycosis. [1] The mortality of patients in this series was approximately 50%, despite optimal surgical and medical management. This is similar to earlier series from across the globe. In patients with central nervous system involvement, prolonged neutropenia or disseminated disease, mortality is 80-100% despite therapy. [2] Because of its unacceptably high mortality rate, it is desirable to develop new therapeutic strategies to treat invasive mucormycosis. It is in this setting, that we must look at iron chelation, as the next possible therapeutic intervention to improve mortality and morbidity in this disorder.

Iron is required virtually by all microbial pathogens for growth and virulence. Mucorales have an exceptional iron requirement for growth and pathogenicity. [2] The potential therapeutic role of iron chelation therapy for mucormycosis was initially obscured by the paradoxically increased risk of developing mucormycosis during treatment with deferoxamine. [3] This is because, while deferoxamine is an iron chelator from the perspective of the human host, it serves as a xenosiderophore to Mucorales, which are able to strip the iron from the chelator through an energy-dependent process. However, other iron chelators do not act as iron siderophores for Mucorales. Treatment of Rhizopus -infected mice with the iron chelator deferiprone markedly improved survival. It was shown in this study that deferiprone was as effective as liposomal amphotericin B in reducing fungal burden and improving survival. [4]

In a more recent study involving the oral iron chelator deferasirox, when administered to diabetic ketoacidotic or neutropenic mice with mucormycosis, it significantly improved survival and decreased tissue fungal burden, with an efficacy similar to that of liposomal amphotericin B. [5] Most importantly, deferasirox synergistically improved survival and reduced tissue fungal burden when combined with liposomal amphotericin B.

This data from animal studies suggests the possibility of a role for iron chelation in the treatment of mucor mycosis, in addition to standard anti-fungal therapy and surgery. There is a need for trials of this drug to establish usefulness in humans with this infection.

 
  References Top

1.Jayalakshmi SS, Reddy RG, Borgohain R, Subramanyam C, Panigrahi M, Sundaram C, et al . Predictors of mortality in rhinocerebral mycosis. Neurol India 2007;55:292-7.  Back to cited text no. 1    
2.Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation and management . Clin Microbiol Rev 2005 ; 18 : 556-69.  Back to cited text no. 2    
3.Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Centinieaux B, Verdonck A, et al . Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993;91:1979-86.  Back to cited text no. 3    
4.Ibrahim AS, Edwards JE Jr, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006;58:1070-3.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]
5.Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, et al . The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007;117:2649-57.  Back to cited text no. 5  [PUBMED]  [FULLTEXT]




 

Top
Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow